Description:

1 Year Trial Telmisartan 80 mg Versus Valsartan 160 mg in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy see http://clinicaltrials.gov/ct2/show/study/NCT00153023

Link:

http://clinicaltrials.gov/ct2/show/study/NCT00153023

Keywords:
Versions (2) ▾
  1. 11/22/11
  2. 3/25/14
Uploaded on:

March 25, 2014

DOI:
No DOI assigned. To request one pleaselog in.
License:
Creative Commons BY 4.0
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Eligibility NCT00153023 Type 2 diabetes mellitus

Details

Eligibility Hypertension and Diabetes NCT00153023

Inclusion Criteria
30 to 80 Years
Type 2 diabetes mellitus
Hypertension at screening defined as: an average cuff systolic blood pressure > 130 mmHg and/or diastolic blood pressure >80 mmHg in untreated patients OR patients receiving antihypertensive therapy (i.e., medications specifically prescribed to treat hypertension)
Overt nephropathy defined by 24 hour proteinuria >= 900 mg and by serum creatinine below 265 mol/l (3.0 mg/dl)
Back to the top of the page